Bioniche Life Sciences Inc.

Bioniche Urology IP Inc.

Bionicrie Life Sciences, Inc.

Telesta Therapeutics IP Inc.

Mario C Filion

Nigel C Phillips

Zdenek Richard Holan

Iqubal Velji

Danbing Ke

Stéphanie Reader

Mohamed Elrafih

Andrea C Herréra Gayol

The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.

Bacterial ribonucleic acid cell wall compositions and methods of making and using them

The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria.

The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.

Oligonucleotide compositions and their use to induce apoptosis

A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG), (GT), a(GT)b, a(GA)b, and a(GC)b, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.

Modulation of Fas and FasL expression

The present invention provides a composition comprising a 5'-OH, 3&#x2032;-TEG cholesteryl synthetic sequence wherein the sequence is SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8. The present invention provides methods of using this composition for induction of response in a cell, including but not limited to inhibition of cellular proliferation, induction of cell cycle arrest, induction of caspase activation, cleavage of poly(ADP-ribose) polymerase, induction of apoptosis or modulation of extracellular matrix-cell interactions, or combinations thereof, in cancer cells or synovial cells, and methods of using this composition for treating disease.

Therapeutically useful triethyleneglycol cholesteryl oligonucleotides

The present invention relates to 3'-OH, 5&#x2032;-OH polynucleotide sequence compositions and methods for activating an immune response in an individual, and more preferably, for activating antigen presenting cells in the individual. In one embodiment, the antigen presenting cell is a dendritic cell. The present invention also includes compositions and methods for activating dendritic cells in vitro. These dendritic cells may then be administered to an individual. Preferred 3&#x2032;-OH, 5&#x2032;-OH polynucleotide sequences comprise six bases wherein at least 50% of the bases are guanine and the 5&#x2032; base is guanine. The compositions may comprise a phosphodiester or phosphorothioate backbone.

Oligonucleotide compositions and their use for the modulation of immune responses

The present invention facilitates in silico evaluation of molecules for biological activity by providing a computer-based method to predict whether oligonucleotides may possess biological activity and the efficacy of the biological activity based on the three-dimensional structure and charge characteristics of the oligonucleotides. Biological activities include, but are not limited to, cellular proliferation, induction of cell cycle arrest and apoptosis.

Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

The present invention provides a composition and method comprising a 2&#x2013;20 base 3'-OH, 5&#x2032;-OH synthetic oligonucleotide (sequence) selected from the group consisting of (GT), (TG), a(GT), a(TG), (GT)b, (TG)b, a(GT)b, a(TG)b, wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12, a and b are one or more As, Cs, Gs or Ts and wherein the sequence induces a response selected from the group consisting of induction of cell cycle arrest, inhibition of proliferation, activation of caspases and induction of apoptosis in cancer cells and production of cytokines by immune system cells.

Therapeutically useful synthetic oligonucleotides

The present invention relates to a composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.

Hyaluronic acid in the treatment of cancer

The present invention provides compositions comprising a 3'-OH, 5&#x2032;-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

Oligonucleotide compositions and their use to induce differentiation of cells

The present invention relates to a mycobacterial deoxyribonucleic acid (B-DNA) preserved and complexed on the mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the BCC is effective in treating an inflammation in an animal having an inflammation. More particularly, the present invention relates to adeoxyribonucleic acid (M-DNA) preserved and complexed oncell wall (MCC) and a pharmaceutically acceptable carrier, wherein the MCC is effective in treating an inflammation in an animal having an inflammation.

Method for the treatment of inflammation

The present invention relates to a composition and method comprising ( )-DNA (M-DNA), M-DNA preserved and complexed on cell wall (MCC), a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein the M-DNA and the MCC induce cell cycle arrest in proliferating cancer cells, inhibit proliferation of cancer cells, induce apoptosis in cancer cells and potentiate the antineoplastic effect of the chemotherapeutic agent on cancer cells.

Growing community of inventors

Laval, Canada

Mario C Filion